Share

April 29, 2014; 82 (17) Editorial

Natalizumab discontinuation in the increasing complexity of multiple sclerosis therapy

Maria Pia Sormani, Nicola De Stefano
First published March 28, 2014, DOI: https://doi.org/10.1212/WNL.0000000000000369
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
335

Share

Article Information

vol. 82 no. 17 1484-1485
DOI: 
https://doi.org/10.1212/WNL.0000000000000369
PubMed: 
24682968
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published March 28, 2014.

Article Versions

Copyright & Usage: 
© 2014 American Academy of Neurology

Author Disclosures

    1. Maria Pia Sormani, PhD and
    2. Nicola De Stefano, MD
  1. Maria Pia Sormani, PhD and
    2. Scientific Advisory Boards:

    1. Commercial entity: BIOGEN IDEC

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Merck Serono

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Merck Serono, Actelion, Biogen Idec, Synthon, Allozyne, TEVA, Novartis

    Speakers' Bureaus:

    1. Teva, Merck Serono, Biogen Idec, Novartis

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Nicola De Stefano, MD
    3. Scientific Advisory Boards:

    1. Prof. N. De Stefano serves on scientific advisory boards for Merck- Serono.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Travel expense refunds from Teva and Merck-Serono.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Honoraria for lectures from Teva, BioMS, Biogen-Idec, Bayer Schering Pharma and Merck-Serono.

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Health Sciences (M.P.S.), University of Genova; and the Department of Medicine Surgery and Neuroscience (N.D.S.), University of Siena, Italy.
  1. Correspondence to Dr. Sormani: mariapia.sormani{at}unige.it
View Full Text

Article usage

Article usage: March 2014 to May 2022

AbstractFullPdfSource
Mar 2014164038Highwire
Apr 201448841120Highwire
May 20142705173Highwire
Jun 2014951222Highwire
Jul 201465169Highwire
Aug 20144585Highwire
Sep 20145467Highwire
Oct 20143835Highwire
Nov 20142344Highwire
Dec 20143633Highwire
Jan 20154133Highwire
Feb 20151301Highwire
Mar 20153400Highwire
Apr 20154023Highwire
May 20154243Highwire
Jun 20152811Highwire
Jul 20151701Highwire
Aug 20152312Highwire
Sep 20151632Highwire
Oct 20151402Highwire
Nov 2015931Highwire
Dec 20151001Highwire
Jan 2016801Highwire
Feb 20161103Highwire
Mar 2016900Highwire
Apr 2016810Highwire
May 2016900Highwire
Jun 2016800Highwire
Jul 20161223Highwire
Aug 20161310Highwire
Sep 20161000Highwire
Oct 20161922Highwire
Nov 20161102Highwire
Dec 2016800Highwire
Jan 20171610Highwire
Feb 2017310Highwire
Mar 2017612Highwire
Apr 2017900Highwire
May 20171200Highwire
Jun 20171000Highwire
Jul 2017500Highwire
Aug 2017500Highwire
Sep 20171000Highwire
Oct 20171300Highwire
Nov 20171011Highwire
Dec 2017910Highwire
Jan 2018802Highwire
Feb 20181500Highwire
Mar 20181601Highwire
Apr 2018610Highwire
May 20181111Highwire
Jun 2018701Highwire
Jul 2018600Highwire
Aug 2018700Highwire
Sep 2018700Highwire
Oct 20181400Highwire
Nov 20181310Highwire
Dec 20181600Highwire
Jan 2019800Highwire
Feb 20191020Highwire
Mar 20191200Highwire
Apr 20192400Highwire
May 20191020Highwire
Jun 2019500Highwire
Jul 2019700Highwire
Aug 2019900Highwire
Sep 2019500Highwire
Oct 20191100Highwire
Nov 20191101Highwire
Dec 2019901Highwire
Jan 2020800Highwire
Feb 2020400Highwire
Mar 2020300Highwire
Apr 2020800Highwire
May 2020110Highwire
Jun 2020700Highwire
Jul 2020600Highwire
Aug 2020200Highwire
Sep 2020321Highwire
Oct 2020700Highwire
Nov 2020611Highwire
Dec 2020700Highwire
Jan 2021700Highwire
Feb 20211400Highwire
Mar 20211100Highwire
Apr 2021800Highwire
May 2021200Highwire
Jun 20211000Highwire
Jul 20211000Highwire
Aug 2021700Highwire
Sep 20211312Highwire
Oct 20211300Highwire
Nov 20211100Highwire
Dec 2021411Highwire
Jan 2022900Highwire
Feb 20221701Highwire
Mar 2022601Highwire
Apr 20221401Highwire
May 2022700Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me